UCB (STU:UNC) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
90 GF Score
Price €249.70
GF Value €212.38
Valuation Modestly Overvalued
View Full Analysis

What is UCB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:UNC
90GF Score
UCB SA STU:UNC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €249.70 is trading 17.6% above its estimated GF Value™ of €212.38. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Short Ratio:
  • GF Value™: €212.38 vs. price of €249.70 (17.6% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score

Get the complete analysis for STU:UNC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€249.70
Price
€212.38
GF Value